Figures & data
Table I. The WHO 2010 classification for neuroendocrine neoplasms (NEN) of the digestive system.
Figure 2. Comparison of the resolution between SRS and PET/CT. A 56-year-old woman with a small intestinal NET G2 since 10 years with known liver metastases and peritoneal carcinomatosis. In picture 2A, SRS depicts only liver metastases, while PET/CT with 68Ga-DOTATATE performed one month later, displayed in picture 2B, shows extensive supra- and infra-diaphragmatic lymph node involvement as well as pleural and bone metastases. During the time period between the investigations the patient had radiologically, biochemically and clinically stable disease.
![Figure 2. Comparison of the resolution between SRS and PET/CT. A 56-year-old woman with a small intestinal NET G2 since 10 years with known liver metastases and peritoneal carcinomatosis. In picture 2A, SRS depicts only liver metastases, while PET/CT with 68Ga-DOTATATE performed one month later, displayed in picture 2B, shows extensive supra- and infra-diaphragmatic lymph node involvement as well as pleural and bone metastases. During the time period between the investigations the patient had radiologically, biochemically and clinically stable disease.](/cms/asset/452b2973-cfae-4aa9-90ce-ffcb917af071/ionc_a_941999_f0002_b.gif)
Figure 3. Treatment algorithm for the systemic treatment of pancreatic NETs. *indicates treatment regimens with either streptozotocin + 5-fluourouracil or temozolomide +/2 capecitabine. Debulking treatment, such as surgery, radiofrequency ablation and liver embolisation are not included in the algorithm.
![Figure 3. Treatment algorithm for the systemic treatment of pancreatic NETs. *indicates treatment regimens with either streptozotocin + 5-fluourouracil or temozolomide +/2 capecitabine. Debulking treatment, such as surgery, radiofrequency ablation and liver embolisation are not included in the algorithm.](/cms/asset/8e6d064f-d019-4fa7-a5bb-034af3ca979c/ionc_a_941999_f0003_b.gif)